Association of Mismatch Repair Status with Survival and Response to Neoadjuvant Chemo(radio)therapy in Rectal Cancer

Overview

Journal NPJ Precis Oncol

Publisher Springer Nature

Specialty Oncology

Date 2020 Sep 23

PMID 32964128

Citations 13

Authors

Shu-Biao Ye

Yi-Kan Cheng

Lin Zhang

Yi-Feng Zou

Ping Chen

Yan-Hong Deng

Yan Huang

Jian-Hong Peng

Xiao-Jian Wu

Ping Lan

Affiliations

Soon will be listed here.

Abstract

Prior reports have indicated that defective mismatch repair (MMR) has a favorable impact on outcome in colorectal cancer patients treated with surgery, immunotherapy, or adjuvant chemotherapy. However, the impact of MMR status on response to neoadjuvant radiotherapy in rectal cancer is not well understood. Here we report that dMMR was associated with improved disease-free survival (DFS) ( = 0.034) in patients receiving neoadjuvant chemotherapy (NCT). Patients with dMMR tumors who received neoadjuvant chemoradiotherapy (NCRT) achieved significantly worse DFS ( = 0.026) than those treated with NCT. Conversely, NCRT improved DFS ( = 0.043) in patients with pMMR tumors, especially for stage III disease with improved DFS ( = 0.02). The presence of dMMR was associated with better prognosis in rectal cancer patients treated with NCT. NCT benefited patients with dMMR tumors; while NCRT benefited patients with stage III disease and pMMR tumors. Patients stratified by MMR status may provide a more tailored approach to rectal cancer neoadjuvant therapy.

Citing Articles

Proteomic Analysis of Plasma Exosomes Enables the Identification of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease.

Zhang H, Wu J, Gan J, Wang W, Liu Y, Song T Thorac Cancer. 2025; 16(1):e15517.

PMID: 39778061 PMC: 11717053. DOI: 10.1111/1759-7714.15517.

Landscape of Biomarkers and Pathologic Response in Rectal Cancer: Where We Stand?.

Ocanto A, Teja M, Amorelli F, Counago F, Gomez Palacios A, Alcaraz D Cancers (Basel). 2024; 16(23).

PMID: 39682232 PMC: 11640609. DOI: 10.3390/cancers16234047.

Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients.

Feng Y, Ma W, Zang Y, Guo Y, Li Y, Zhang Y Nat Commun. 2024; 15(1):10259.

PMID: 39592630 PMC: 11599708. DOI: 10.1038/s41467-024-54710-3.

Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone.

Ni K, Zhan Y, Liu Z, Yuan Z, Wang S, Zhao X BMC Cancer. 2023; 23(1):1013.

PMID: 37864137 PMC: 10588073. DOI: 10.1186/s12885-023-11525-7.

Organ Preservation in MSS Rectal Cancer.

Gao Y, Wu A Clin Colon Rectal Surg. 2023; 36(6):430-440.

PMID: 37795468 PMC: 10547535. DOI: 10.1055/s-0043-1767710.

References

Fotheringham S, Mozolowski G, Murray E, Kerr D . Challenges and solutions in patient treatment strategies for stage II colon cancer. Gastroenterol Rep (Oxf). 2019; 7(3):151-161. PMC: 6573795. DOI: 10.1093/gastro/goz006. View

Bosse D, Mercer J, Raissouni S, Dennis K, Goodwin R, Jiang D . PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium. Clin Colorectal Cancer. 2016; 15(3):243-9. DOI: 10.1016/j.clcc.2016.02.003. View

Delitto D, George Jr T, Loftus T, Qiu P, Chang G, Allegra C . Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. J Natl Cancer Inst. 2017; 110(5):460-466. PMC: 6279292. DOI: 10.1093/jnci/djx228. View

Jiang D, Wang X, Wang Y, Philips D, Meng W, Xiong M . Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. Virchows Arch. 2019; 475(1):39-47. DOI: 10.1007/s00428-019-02576-y. View

Du C, Zhao J, Xue W, Dou F, Gu J . Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy. Histopathology. 2013; 62(5):723-30. DOI: 10.1111/his.12069. View

Bertagnolli M, Niedzwiecki D, Compton C, Hahn H, Hall M, Damas B . Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009; 27(11):1814-21. PMC: 2668707. DOI: 10.1200/JCO.2008.18.2071. View

Lindor N, Burgart L, Leontovich O, Goldberg R, Cunningham J, Sargent D . Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002; 20(4):1043-8. DOI: 10.1200/JCO.2002.20.4.1043. View

de Rosa N, Rodriguez-Bigas M, Chang G, Veerapong J, Borras E, Krishnan S . DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol. 2016; 34(25):3039-46. PMC: 5012714. DOI: 10.1200/JCO.2016.66.6826. View

Ribic C, Sargent D, Moore M, Thibodeau S, French A, Goldberg R . Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003; 349(3):247-57. PMC: 3584639. DOI: 10.1056/NEJMoa022289. View

10.

Austin P . The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009; 29(6):661-77. DOI: 10.1177/0272989X09341755. View

11.

Altman D, McShane L, Sauerbrei W, Taube S . Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012; 9(5):e1001216. PMC: 3362085. DOI: 10.1371/journal.pmed.1001216. View

12.

Karagkounis G, Thai L, Mace A, Wiland H, Pai R, Steele S . Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer. Ann Surg. 2019; 269(6):1117-1123. DOI: 10.1097/SLA.0000000000002719. View

13.

Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C . Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 30(16):1926-33. DOI: 10.1200/JCO.2011.40.1836. View

14.

Oh C, Kim J, Kang J, Kim S, Kim K, Hong Y . Prognostic Value of the Microsatellite Instability Status in Patients With Stage II/III Rectal Cancer Following Upfront Surgery. Clin Colorectal Cancer. 2018; 17(4):e679-e685. DOI: 10.1016/j.clcc.2018.07.003. View

15.

Meillan N, Vernerey D, Lefevre J, Manceau G, Svrcek M, Augustin J . Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2019; 105(4):824-833. DOI: 10.1016/j.ijrobp.2019.07.057. View

16.

Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A . Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2009; 21(4):772-780. DOI: 10.1093/annonc/mdp383. View

17.

Benson A, Venook A, Al-Hawary M, Cederquist L, Chen Y, Ciombor K . Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16(7):874-901. PMC: 10203817. DOI: 10.6004/jnccn.2018.0061. View

18.

Zhang J, Huang M, Cai Y, Wang L, Xiao J, Lan P . Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2019; 18(4):238-244. DOI: 10.1016/j.clcc.2019.07.001. View

19.

Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L . Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. J Clin Oncol. 2019; 37(34):3223-3233. PMC: 6881102. DOI: 10.1200/JCO.18.02309. View

20.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View